Welcome to our dedicated page for OKYO PHARMA news (Ticker: OKYO), a resource for investors and traders seeking the latest updates and insights on OKYO PHARMA stock.
OKYO Pharma Limited (NASDAQ: OKYO) is a clinical-stage, ophthalmology-focused biopharmaceutical company developing novel therapies for neuropathic corneal pain (NCP), dry eye disease, and other ocular inflammatory conditions. Its news flow centers on the progress of its lead investigational drug candidate, urcosimod, and related clinical, regulatory, and corporate developments.
Visitors to this news page can review company-issued announcements about Phase 2 clinical trial results, including data showing reductions in neuropathic corneal pain and exploratory findings on corneal nerve structure in NCP patients treated with urcosimod. OKYO also reports on earlier Phase 2 results in dry eye disease, where urcosimod demonstrated statistically significant outcomes on multiple endpoints in a 240-patient trial.
In addition to clinical data, OKYO’s news releases cover planned development milestones such as the registration pathway and a proposed multiple-ascending-dose, multi-center trial in approximately 100 NCP patients, as well as references to urcosimod’s Fast-Track designation and anticipated regulatory interactions. Corporate communications include participation in ophthalmology and life science conferences, such as the Ophthalmology Innovation Summit and BIO-Europe, where management presents updates on urcosimod and the company’s pipeline.
Investors can also find announcements related to share acquisitions by Panetta Partners Limited, an entity with a beneficial interest held by OKYO’s Executive Chairman, as disclosed in both news releases and accompanying Form 6-K filings. Together, these updates provide a view into how OKYO is advancing urcosimod as a potential first-in-class therapy for neuropathic corneal pain and dry eye disease, and how it communicates key milestones to the market.
OKYO Pharma (NASDAQ: OKYO) announced that Panetta Partners Limited, an entity in which Executive Chairman Gabriele Cerrone has a beneficial interest, purchased 10,119 ordinary shares on NASDAQ at $1.59 on March 19, 2026, bringing his total holdings to 10,526,416 shares.
The transaction is an insider purchase and updates the chairman's aggregate beneficial ownership.
OKYO Pharma (NASDAQ: OKYO) said on March 19, 2026 that Non-Executive Director John Brancaccio purchased 5,000 ordinary shares on NASDAQ at $1.61 per share, increasing his total holding to 31,201 shares.
The disclosure reflects an insider purchase by a director in the company developing therapies for neuropathic corneal pain and inflammatory eye diseases.
OKYO Pharma (NASDAQ: OKYO) said Gary Jacob, Chief Development Officer and director, acquired 30,980 ordinary shares on NASDAQ at $1.59 on March 19, 2026, increasing his total holding to 108,920 shares.
The purchase is a direct insider buy by a senior officer and board member, showing personal investment in the company's clinical-stage programs for neuropathic corneal pain and inflammatory eye diseases.
OKYO Pharma (Nasdaq: OKYO) reported exploratory Phase 2a patient-reported quality-of-life (QoL) improvements with 0.05% urcosimod for neuropathic corneal pain (NCP). Treatment (n=6) showed greater mean improvements versus placebo (n=6) in emotional well-being, mood, and time spent thinking about eye pain.
Findings will be presented at ARVO 2026 and the company plans larger confirmatory Phase 2b/3 studies to validate these results.
OKYO (Nasdaq: OKYO) announced that an abstract on urcosimod for neuropathic corneal pain (NCP) was accepted for presentation at ARVO 2026 (May 3-7, Denver).
OKYO reported Phase 2a proof-of-concept results showing clinically meaningful pain reduction (VAS), quality-of-life improvement, potential corneal nerve restoration, FDA Fast Track designation, IND clearance, and a planned ~150-patient Phase 2b/3 trial expected to start in the coming months.
OKYO Pharma (Nasdaq: OKYO) priced an underwritten public offering of 10,815,000 ordinary shares at $1.85 per share, raising gross proceeds of approximately $20 million. The underwriter has a 30-day option for an additional 1,622,250 shares (proceeds up to ~$23 million).
The offering is expected to close on or about February 17, 2026. Net proceeds will be used primarily for clinical development, general corporate purposes and working capital. Piper Sandler is sole manager; securities offered under an effective Form F-3 (File No. 333-293145).
OKYO Pharma (Nasdaq: OKYO) announced an underwritten public offering of ordinary shares on February 12, 2026. The company will sell all shares offered, with an underwriter option for up to 15% additional shares for 30 days. Piper Sandler is sole book-running manager.
The offering is subject to market conditions and may not be completed. Proceeds are intended primarily for clinical development, general corporate purposes and working capital. The sale is being made from a Form F-3 shelf registration declared effective on February 10, 2026.
OKYO Pharma (Nasdaq: OKYO) transitioned its At-The-Market (ATM) equity offering facility to Leerink Partners as exclusive sales agent, replacing B. Riley Securities. The ATM lets OKYO sell common shares opportunistically at prevailing market prices to support clinical development, including lead candidate urcosimod.
Leerink will receive a 3.0% commission on gross proceeds. Any sales will be made pursuant to a prospectus supplement and base prospectus filed with the SEC. The company emphasized the move enhances financial flexibility without committing to a fixed equity raise.
OKYO Pharma (Nasdaq: OKYO) appointed Flavio Mantelli, MD, PhD as Chief Medical Officer to lead clinical and regulatory strategy for urcosimod in neuropathic corneal pain (NCP). Mantelli previously led development and approval of Oxervate, which reached $1 billion sales in 2024. OKYO plans a ~150-subject Phase 2b/3 multiple-dose study expected to start in H1 2026; urcosimod holds FDA Fast Track designation and an authorized compassionate use pathway for NCP.
OKYO Pharma (Nasdaq: OKYO) announced acceptance of a Phase 2 urcosimod abstract for presentation at the 2026 ASCRS Annual Meeting on April 11, 2026 in Washington, DC. The abstract reports efficacy and safety results from a proof-of-concept pilot Phase 2 study, including pain reduction and corneal nerve health trends.
The company notes urcosimod previously received the first IND to treat NCP and FDA fast track designation, and expects to initiate a 150-patient Phase 2b/3 multiple-dose study in the first half of 2026.